EPCAM and digestive system neoplasm: IMC001, an anti-EpCAM CAR-T therapy, as monotherapy or in combination with immune checkpoint inhibitors, is currently in Phase I and II trials for EpCAM+ tumors of the digestive system (NCT05028933, NCT04196465).